The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials
The DOI matches its Crossref record, with a small difference in title or year; 48 of the 48 references it cites were found in a registry or an index.
Abstract
: Diabetic kidney disease is a serious microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease in western countries. New therapeutic agents are needed to delay its onset and progression. Recent literature suggests that sodium-glucose cotransporter 2 (SGLT-2) inhibitors may have renoprotective effects. Our aim was to systematically review the effect of SGLT-2 inhibitors on albuminuria and proteinuria in patients with diabetes mellitus. Studies were identified by search in major electronic databases, clinical trial registers, and sources of gray literature. We included randomized controlled trials of currently approved SGLT-2 inhibitors with a duration of at least 12 weeks. The primary outcome was the between-groups difference in the proportional (%) change of albuminuria or proteinuria between baseline and end of treatment. SGLT-2 inhibitors were associated with statistically significant reduction in albuminuria compared to placebo or active control [weighted mean difference (WMD) -25.39%, 95% confidence interval (CI) -34.17 to -16.62] (15 studies, N = 17 540 patients). When trials were stratified according to the level of baseline albuminuria, reduction in urine albumin-to-creatinine ratio was more prominent in randomized controlled trials in patients with moderately (WMD -40.78%, 95% CI -63.21 to -18.34) or severely increased albuminuria (WMD -36.40%, 95% CI -51.53 to -21.26). Only one study reported data for urine protein-to-creatinine ratio. Finally, SGLT-2 inhibitors reduced systolic and diastolic blood pressure by 4.43 mmHg (95% CI -5.24 to -3.63) and 1.81 mmHg (95% CI -2.38 to -1.23), respectively.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“CVOTs with DPP-4 inhibitors achieved non-inferiority compared with placebo for the occurrence of MACE.1044–1046”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1046]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · cited 2×
“The EMPA-REG OUTCOME study randomized 7028 patients with T2DM at high cardiovascular risk to 10 or 25 mg of empagliflozin or placebo [38].”
MethodResultEstimating the mean and variance from the median, range, and the size of a sample
Hozo, S. P., Djulbegovic, B., & Hozo, I. (2005) · BMC Medical Research Methodology · doi:10.1186/1471-2288-5-13 · Cited by 9,062
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830 · cited 2×
“Similarly, favorable were the results of the Canagliflozin Cardiovascular Assessment Study (CANVAS) and CANVAS-renal trials, which randomized 10 142 patients with type 2 diabetes at high cardiovascular risk to canagliflozin or placebo for 188 weeks [15].”
ResultEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 2×
“7 and 11% of population, respectively [14].”
ResultPlasma aldosterone regulation in anephric man
Walker, W. G., & Cooke, C. R. (1973) · Kidney International · doi:10.1038/ki.1973.1 · Cited by 1,841
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376 · cited 3×
“Indeed, recent trials with SGLT-2 inhibitors have displayed significant ( 30–40%) reduction in urine albumin excretion (UAE), independent of the effects on BP or glucose control [11,13].”
BackgroundCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329 · cited 1×
“[49] showed that empagliflozin treatment for 8 weeks resulted in reduction of baseline inulin-measured GFR by 33ml/min per 1.”
BackgroundSodium–Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes: A Systematic Review and Meta-analysis
Vasilakou, D., Karagiannis, T., Athanasiadou, E., Mainou, M., Liakos, A., Bekiari, E., Sarigianni, M., Matthews, D. R., & Tsapas, A. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-159-4-201308200-00007 · Cited by 911
The hyperfiltration theory: A paradigm shift in nephrology
Brenner, B. M., Lawler, E. V., & Mackenzie, H. S. (1996) · Kidney International · doi:10.1038/ki.1996.265 · Cited by 868 · cited 1×
“In brief, diabetes mellitus is long known to promote renal injury through afferent vasodilation and increase in intraglomerular pressure and albuminuria via several mechanisms [36,45].”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700
Research works printed but not linked: 1
- 2013, 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease., Kidney Int Suppl, 3, 1
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Self-citationBlonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Sarafidis, P., Ferro, C. J., Morales, E., Ortiz, A., Malyszko, J., Hojs, R., Khazim, K., Ekart, R., Valdivielso, J., Fouque, D., et al. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfy407 · Cited by 204
“These effects of SGLT-2 inhibitors on reduction of glomerular hyperfiltration and intraglomerular pressure are supported by the EMPA-REG OUTCOME and CANVAS trials, as well as several other studies, showing decrease in urine albumin excretion [97, 98].”
ResultSelf-citationKarakasis, P., Patoulias, D., Fragakis, N., Klisic, A., & Rizzo, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15410 · Cited by 65
“39 Similarly, GLP-1RA treatment in T2DM has also been documented to exert significant renal benefits for the affected subjects, providing a substantial risk reduction across a number of surrogate renal endpoints, including progression to end-stage CKD and death because of renal causes.”
BackgroundSlieker, R. C., van der Heijden, A. A. W. A., Siddiqui, M. K., Langendoen‐Gort, M., Nijpels, G., Herings, R. M. C., Feenstra, T., Moons, K. G. M., Bell, S., Elders, P. J. M., et al. (2021) · BMJ · doi:10.1136/bmj.n2134 · Cited by 70
Metadata
- Authors
- Piperidou, A., Sarafidis, P., Boutou, A., Thomopoulos, C., Loutradis, C., Alexandrou, M. E., Tsapas, A., & Karagiannis, A.
- Affiliations
- Aristotle University of Thessaloniki (GR)
- G. Papanikolaou General Hospital (GR)
- General-Maternity District Hospital Helena Venizelou (GR)
- Papageorgiou General Hospital (GR)
- Corresponding author
- Sarafidis, Pantelis
- ORCID
- Venue
- Journal of Hypertension
- Published
- 2019-07
- Volume
- 37
- Issue
- 7
- Pages
- 1334-1343
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2911444988
- Cited by
- 72
- References
- 48
- Citations by year
- 2026: 9 · 2025: 11 · 2024: 9 · 2023: 12 · 2022: 14 · 2021: 8 · 2020: 6 · 2019: 3
- FWCI
- 1.21
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Hypertension (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- SGLT2 inhibitors, albuminuria, proteinuria, diabetic nephropathy, diabetes mellitus, renal protection, albumin-creatinine ratio, blood pressure reduction, end-stage renal disease
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Albuminuria, Blood Pressure, Diabetic Nephropathies, Humans, Hypoglycemic Agents, Proteinuria, Randomized Controlled Trials as Topic, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. https://app.cochat.ai/papers/10.1097/hjh.0000000000002050
- The paper
- Piperidou, A., Sarafidis, P., Boutou, A., Thomopoulos, C., Loutradis, C., Alexandrou, M. E., Tsapas, A., & Karagiannis, A. (2019). The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Journal of Hypertension. https://doi.org/10.1097/hjh.0000000000002050
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.